Share on StockTwits

Research analysts at B. Riley started coverage on shares of BioLineRx (NASDAQ:BLRX) in a report released on Friday, American Banking and Market News reports. The firm set a “buy” rating and a $4.00 price target on the stock. B. Riley’s price target indicates a potential upside of 92.93% from the company’s current price.

Shares of BioLineRx (NASDAQ:BLRX) opened at 2.0733 on Friday. BioLineRx has a 52 week low of $1.55 and a 52 week high of $3.34. The stock has a 50-day moving average of $2.28 and a 200-day moving average of $2.64. The company’s market cap is $70.2 million.

BioLineRx (NASDAQ:BLRX) last released its earnings data on Monday, March 17th. The company reported ($0.20) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.15) by $0.05. Analysts expect that BioLineRx will post $-0.49 EPS for the current fiscal year.

Separately, analysts at Maxim Group initiated coverage on shares of BioLineRx in a research note on Friday. They set a “buy” rating on the stock.

BioLineRX Ltd. is an Israel-based company engaged in identifying and following the critical pathway to commercialization of therapeutic compounds.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.